Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
1.
Heart ; 91(10): 1262-4, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16162609

RESUMEN

Despite the clinical benefits and safety profile of primary percutaneous coronary intervention (PCI), the health care system in the UK has been slow to adopt this strategy as first line management for ST segment elevation myocardial infarction. The cost implications of a 24 hour a day, seven days per week primary PCI service and the absence of an existing efficient working model within the National Health Service (NHS) framework are two of the major deterrents for provision of such a service. The existent cost effectiveness data for primary PCI is critically reviewed, with particular reference to the NHS.


Asunto(s)
Angioplastia Coronaria con Balón/economía , Infarto del Miocardio/terapia , Medicina Estatal/economía , Costos y Análisis de Costo , Europa (Continente) , Predicción , Humanos , Infarto del Miocardio/economía , América del Norte , Medicina Estatal/tendencias , Reino Unido
2.
Am Heart J ; 149(1): 13-9, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15660030

RESUMEN

BACKGROUND: Patients with diabetes have an increased incidence and severity of ischemic heart disease, which leads to an increased requirement for coronary revascularization. Comparative information regarding mode of revascularization--coronary artery bypass graft surgery surgery (CABG) or percutaneous coronary intervention (PCI)--is limited, mainly confined to a subanalysis of the Bypass Angioplasty Revascularization (BARI) trial, suggesting a mortality benefit of CABG over PCI. No prospective trial has specifically compared these modes of revascularization in patients with diabetes. OBJECTIVE: The Coronary Artery Revascularisation in Diabetes (CARDia) trial is designed to address the hypothesis that optimal PCI is not inferior to modern CABG as a revascularization strategy for diabetics with multivessel or complex single-vessel coronary disease. The primary end point is a composite of death, nonfatal myocardial infarction, and cerebrovascular accident at 1 year. METHOD: A total of 600 patients with diabetes are to be randomized to either PCI or CABG, with few protocol restrictions on operative techniques or use of new technology. This gives a power of 80% to detect non-inferiority of PCI assuming that the PCI 1-year event rate is 9%. A cardiac surgeon and a cardiologist must agree that a patient is suitable for revascularization by either technique prior to recruitment into the study. Twenty-one centers in the United Kingdom and Ireland are recruiting patients. Data on cost effectiveness, quality of life, and neurocognitive function are being collected. Long-term (3-5 year) follow-up data will also be collected.


Asunto(s)
Angioplastia Coronaria con Balón , Puente de Arteria Coronaria , Enfermedad Coronaria/terapia , Complicaciones de la Diabetes , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/cirugía , Humanos , Inmunosupresores/administración & dosificación , Estudios Multicéntricos como Asunto , Infarto del Miocardio , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Sirolimus/administración & dosificación , Stents
4.
Heart ; 90(7): 732-8, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15201238

RESUMEN

There are over 1.3 million known diabetic patients in the UK and a similar number who have the disease undiagnosed. Over 90% have non-insulin dependent diabetes mellitus usually characterised by insulin resistance and adult onset. Over half of all diabetic patients die of coronary disease and account for over a fifth of percutaneous coronary intervention (PCI) revascularisation procedures. Despite recent therapeutic advances such as new antiplatelet treatments and drug eluting stents, outcomes for diabetic patients after PCI are still significantly worse than for non-diabetic patients. This article summarises what is known about the pattern and severity of diabetic coronary disease, what mechanisms are responsible for these differences, and whether this information can help explain the poorer prognosis for these patients after PCI and form the basis of interventions to improve outcome.


Asunto(s)
Enfermedad Coronaria , Diabetes Mellitus Tipo 2 , Angiopatías Diabéticas , Angioplastia Coronaria con Balón , Enfermedad Coronaria/etiología , Enfermedad Coronaria/patología , Enfermedad Coronaria/terapia , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/patología , Diabetes Mellitus Tipo 2/terapia , Angiopatías Diabéticas/etiología , Angiopatías Diabéticas/patología , Angiopatías Diabéticas/terapia , Humanos , Pronóstico
5.
Heart ; 85(2): 208-12, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11156674

RESUMEN

OBJECTIVE: Previous studies have suggested that resting myocardial blood flow is within normal limits in most chronically dysfunctional left ventricular segments which improve function after coronary artery revascularisation (hibernating myocardium). The aim of this study was to assess myocardial blood flow and coronary vasodilator reserve in hibernating myocardium before and after coronary revascularisation. PATIENTS AND METHODS: 30 patients with multivessel coronary disease undergoing coronary revascularisation (21 patients with bypass grafting and nine with coronary angioplasty), and 21 age and sex matched healthy volunteers (controls). Myocardial blood flow (MBF, ml/min/g) was measured by positron emission tomography using oxygen-15 water at rest and after dipyridamole (MBFdip, 0.56 mg/kg in four minutes). Coronary vasodilator reserve was calculated as MBFdip/MBF. Regional wall motion was assessed with echocardiography. RESULTS: Before revascularisation there were 48 remote and 275 dysfunctional myocardial segments, of which 163 (59%) improved function after revascularisation (hibernating). In hibernating segments coronary vasodilator reserve before revascularisation was significantly lower than in remote segments (1.97 (0.7), p < 0.0001) and controls (3.2 (1.5), p < 0.0001). In hibernating segments, myocardial blood flow remained unchanged after revascularisation (0.94 (0.3) v 0.95 (0.3) ml/min/g, p = 0.3) while coronary vasodilator reserve increased (1. 47 (0.7) v 1.98 (1.0), p < 0.0001). Myocardial blood flow was similar in remote, hibernating segments before and after revascularisation and in controls. CONCLUSIONS: This study confirms that myocardial blood flow at rest in hibernating myocardium is within normal limits in most segments, and that hibernating myocardium is characterised by an impaired coronary vasodilator reserve which improves significantly after coronary revascularisation.


Asunto(s)
Circulación Coronaria/fisiología , Vasos Coronarios/fisiopatología , Revascularización Miocárdica , Aturdimiento Miocárdico/terapia , Vasodilatación/fisiología , Adulto , Anciano , Angioplastia Coronaria con Balón , Puente de Arteria Coronaria , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Aturdimiento Miocárdico/diagnóstico , Aturdimiento Miocárdico/fisiopatología , Función Ventricular Izquierda/fisiología
7.
Heart ; 82(2): 210-6, 1999 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10409538

RESUMEN

OBJECTIVES: To determine the efficacy of coronary angioplasty as the sole method of revascularisation in patients with coronary artery disease and chronically dysfunctional but viable myocardium (hibernating myocardium), and to assess the effect of restenosis on functional outcome. DESIGN AND PATIENTS: 24 consecutive patients with hibernating myocardium were studied. Positron emission tomography was used to assess myocardial viability, blood flow, and flow reserve. One patient refused angioplasty, one had bypass surgery, and one died while waiting for an elective procedure. The procedure failed in three patients. The remaining 18 patients had repeat echocardiography, 15 had repeat coronary angiography, and nine had repeat assessments of blood flow and flow reserve at mean (SD) 17 (2) weeks after angioplasty. In three patients restenosis was documented. RESULTS: The wall motion score index in the revascularised territories improved from 1.71 (0.37) to 1.34 (0.47) (p = 0.008). Thirty of 51 dysfunctional segments improved in territories without restenosis compared with three of 14 in restenosed territories (p = 0.001). Hibernating and normal segments had comparable flows (0.82 (0.26) v 0.89 (0.24) ml/min/g; NS) while flow reserve was lower in hibernating segments (1.55 (0.68) v 2.07 (1.08); p = 0.03). In segments without restenosis flow reserve improved from 2.03 (1.25) to 2.33 (1.4) (p = 0.03). Sensitivity, specificity, and positive and negative predictive accuracy of the viability study were 97%, 77%, 82%, and 96%, respectively. After excluding patients with restenosis, specificity and positive predictive accuracy improved to 90% and 93%. CONCLUSIONS: Angioplasty improves function in hibernating myocardium, and restenosis prevents recovery; hibernating myocardium is characterised by an impairment of flow reserve; restenosis affects the diagnostic accuracy of viability studies.


Asunto(s)
Angioplastia Coronaria con Balón , Aturdimiento Miocárdico/terapia , Adulto , Anciano , Análisis de Varianza , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/terapia , Ecocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aturdimiento Miocárdico/diagnóstico por imagen , Recurrencia , Tomografía Computarizada de Emisión
9.
Circulation ; 96(4): 1152-6, 1997 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-9286943

RESUMEN

BACKGROUND: Glucose-insulin-potassium (GIK) therapy has been advocated for the treatment of acute myocardial infarction. However, the results from the clinical trials have been inconclusive, largely because of the small number of patients recruited and discrepancies between protocols used in these studies. METHOD AND RESULTS: A systematic MEDLINE search for all the randomized placebo-controlled studies of GIK therapy in acute myocardial infarction was made, and a meta-analysis of the mortality data was performed. Fifteen trials were identified, 5 were excluded because of poor randomization, and 1 was excluded because recruitment was limited to diabetic patients. The 9 remaining trials with a total of 1932 patients were included in the analysis. Hospital mortality was reduced from 21% (205 of 972 patients) in the placebo group to 16.1% (154 of 956) in the GIK group (P=.004; odds ratio, 0.72; 95% confidence interval [CI], 0.57 to 0.90). The proportional mortality reduction was 28% (CI, 10% to 43%). The number of lives saved per 1000 patients treated was 49 (95% CI, 14 to 83). CONCLUSIONS: The findings indicate that GIK therapy may have an important role in reducing the in-hospital mortality after acute myocardial infarction. The value of this therapy in the era of thrombolysis and acute revascularization by primary angioplasty can be fully resolved only by conducting a large randomized mortality study.


Asunto(s)
Glucosa/uso terapéutico , Insulina/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Potasio/uso terapéutico , Angioplastia Coronaria con Balón , Humanos , Infarto del Miocardio/mortalidad , Infarto del Miocardio/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Terapia Trombolítica
10.
Am Heart J ; 134(1): 62-8, 1997 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9266784

RESUMEN

Thrombolysis in Myocardial Infarction (TIMI) flow scores were originally devised as semiquantitative angiographic measures of coronary artery perfusion. Several studies have indicated an important relation between different TIMI flow grades at 90 minutes after thrombolysis and clinical outcome. To further evaluate this relation we conducted a metaanalysis of all angiographic, postinfarction trials that studied the relation between individual 90-minute TIMI flow grades and mortality rates. In 4687 pooled patients, the mortality rate was lowest in patients with TIMI grade 3 flow (3.7%) and significantly lower than those with TIMI 2 (6.6%, p = 0.0003; odds ratio 0.55; 95% confidence interval [CI] 0.4% to 0.76%) or TIMI 0/1 flow (9.2%, p < 0.0001; odds ratio 0.38; 95% CI 0.29% to 0.5%). The mortality rate difference between TIMI grade 2 and TIMI grade 0/1 patients was also significant (p = 0.02; odds ratio 0.7; 95% CI 0.51% to 0.94%). This study confirms the importance of achieving rapid and complete reperfusion after acute myocardial infarction with the best outcome associated with 90-minute TIMI 3 flow. Furthermore, it shows that although TIMI 2 flow (partial perfusion) is not equivalent to TIMI 3 flow, it nevertheless still confers a significant survival benefit compared with TIMI flow 0/1.


Asunto(s)
Infarto del Miocardio/tratamiento farmacológico , Reperfusión Miocárdica/clasificación , Índice de Severidad de la Enfermedad , Terapia Trombolítica , Intervalos de Confianza , Angiografía Coronaria , Circulación Coronaria , Vasos Coronarios/fisiopatología , Mortalidad Hospitalaria , Humanos , Infarto del Miocardio/mortalidad , Infarto del Miocardio/fisiopatología , Reperfusión Miocárdica/mortalidad , Oportunidad Relativa , Tasa de Supervivencia , Terapia Trombolítica/mortalidad , Factores de Tiempo , Resultado del Tratamiento , Grado de Desobstrucción Vascular
13.
Br J Hosp Med ; 53(11): 575-80, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7655756

RESUMEN

Thrombolytic therapy has revolutionised the treatment of acute myocardial infarction. This has led to a need for rapid and accurate diagnosis of this condition, provision of a triage protocol to achieve initiation of thrombolytic therapy as soon as the diagnosis has been made, and knowledge of the benefit:risk ratio of thrombolytic therapy in different subgroups of patients to allow the most effective use of these agents without compromising patient safety.


Asunto(s)
Fibrinolíticos/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Electrocardiografía , Fibrinolíticos/efectos adversos , Mortalidad Hospitalaria , Humanos , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/mortalidad , Factores de Tiempo , Triaje
14.
Circulation ; 91(6): 1689-96, 1995 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-7882475

RESUMEN

BACKGROUND: Angiopeptin is a cyclic octapeptide analogue of somatostatin that has been shown to limit myointimal thickening of arteries in balloon injury models and to restore the vasodilating response to acetylcholine. A randomized, double-blind placebo controlled trial was conducted to assess the effect of angiopeptin in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). METHODS AND RESULTS: Patients received a continuous infusion of either placebo or angiopeptin subcutaneously 6 to 24 hours before PTCA and for 4 days after PTCA (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA and for the remaining period). A 1.5-mg bolus dose of placebo or angiopeptin was given at PTCA. Aspirin (acetylsalicylic acid, 150 mg/d) was administered throughout the study period. Coronary angiograms obtained before and after PTCA and at 6-month follow-up were subjected to computerized quantification. Clinical follow-up was performed after 12 months. Primary clinical end points were death, myocardial infarction, coronary artery bypass surgery, or repeat PTCA. In total, 553 patients with 742 lesions were randomized. Clinical follow-up was available for all 553 patients. Angiopeptin decreased the clinical events during 12 months of follow-up from 36.4% in the placebo-treated group to 28.4% in the angiopeptin-treated patients (P = .046). Quantitative angiography after PTCA and at follow-up was available in 423 of 455 patients who underwent successful PTCA. The minimal lumen diameter at follow-up was 1.52 +/- 0.64 mm in the angiopeptin-treated group compared with 1.52 +/- 0.64 mm in the placebo-treated patients (P = .96). The late losses were 0.31 +/- 0.59 and 0.30 +/- 0.62 mm (P = .81) and the restenosis rates (> 50% diameter stenosis at follow-up) were 36% and 37% (P = .85) in the angiopeptin- and placebo-treated groups, respectively. CONCLUSIONS: In this study, angiopeptin significantly decreased the incidence of clinical events, principally the rate of revascularization procedures. In contrast, no significant effect was seen on angiographic variables.


Asunto(s)
Angioplastia Coronaria con Balón , Enfermedad Coronaria/terapia , Oligopéptidos/uso terapéutico , Somatostatina/análogos & derivados , Anciano , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/mortalidad , Método Doble Ciego , Femenino , Estudios de Seguimiento , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Oligopéptidos/efectos adversos , Péptidos Cíclicos , Recurrencia , Somatostatina/efectos adversos , Somatostatina/uso terapéutico
17.
Int J Card Imaging ; 9 Suppl 1: 77-83, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-8409547

RESUMEN

There remains a need to establish adequate protocols for investigating the short- and long-term follow-up of revascularization procedures. For coronary angioplasty the most reliable basis for decision-making in managing patients is the symptomatology of the patient. For bypass surgery a protocol should be established to evaluate patients late, at 5 to 10 years following bypass surgery, in particular those with saphenous vein grafting, as graft and patient survival begins to fall after this period. Investigation after this may be too late for many patients who may already have several occluded grafts and poor left ventricular function, two of the most important prognostic factors post bypass surgery. The improvement and refinement of non-invasive investigations has led to a better understanding of the value and limitations of many of these tests, but it is particularly important that the limitations of many investigation are fully appreciated when they are used to influence clinical decisions. In this regard, a study comparing and integrating the predictive value of the persistence or return to symptoms, a positive non-invasive test, and a positive invasive test would surely prove invaluable.


Asunto(s)
Isquemia Miocárdica/diagnóstico , Revascularización Miocárdica , Angiografía Coronaria , Puente de Arteria Coronaria , Electrocardiografía , Prueba de Esfuerzo , Corazón/fisiología , Pruebas de Función Cardíaca , Humanos , Isquemia Miocárdica/fisiopatología , Isquemia Miocárdica/cirugía , Radioisótopos de Talio
18.
Am Heart J ; 123(4 Pt 1): 1046-54, 1992 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1549969

RESUMEN

During a 2-year period, 136 self-expanding Wallstents were implanted in saphenous vein bypass grafts in 69 patients with end-stage coronary artery disease. All patients had severe symptoms and the majority were poor candidates for either repeat surgery or conventional bypass coronary angioplasty because of unfavorable native anatomy, impaired left ventricular function, or a high-risk bypass lesion anatomy for coronary angioplasty. All procedures were technically successful without major complications and a need for emergency bypass surgery. However, during the hospital stay acute thrombotic complications occurred in seven patients (10%) resulting in one death and acute myocardial infarction in five patients and necessitating emergency repeat PTCA in two patients and repeat CABG in four. Twenty-three patients had serious hemorrhagic complications directly related to the rigorous anticoagulation schedule. Two patients died of fatal cerebral bleeding. During follow-up, another five patients died accounting for a total mortality rate of 12%. At late angiographic follow-up (4.9 +/- 3.4 months, n = 53), 25 patients (47%) had a restenosis (greater than or equal to 50% DS) within or immediately adjacent to the stent, necessitating reintervention in 19 patients (PTCA, n = 12; repeat CABG, n = 7). In the group without stent-related restenosis (n = 28), 15 patients had progression of disease in either the native or bypass vessels leading to recurrence of major anginal symptoms within 1 to 24 months. Ten of these patients required further intervention (stent, n = 6; PTCA, n = 3; repeat CABG, n = 1). Stenting in saphenous coronary bypass grafts can be performed safely with excellent immediate angiographic and clinical results.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Puente de Arteria Coronaria , Oclusión de Injerto Vascular/terapia , Vena Safena/trasplante , Stents , Anciano , Angioplastia Coronaria con Balón , Terapia Combinada , Angiografía Coronaria , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/cirugía , Femenino , Estudios de Seguimiento , Oclusión de Injerto Vascular/diagnóstico por imagen , Oclusión de Injerto Vascular/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Reoperación , Stents/estadística & datos numéricos
19.
Am J Cardiol ; 69(6): 584-91, 1992 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-1536105

RESUMEN

Because many ongoing clinical restenosis prevention trials are using quantitative angiography to assess whether a drug is capable of reducing the amount of intimal hyperplasia, quantitative angiographic risk factors for angiographic luminal narrowing after balloon angioplasty were determined, including stretch and elastic recoil at the dilatation site. Quantitative analysis was performed on 666 lesions in 575 patients during angioplasty and at 6-month follow-up. Stretch was defined as balloon diameter minus minimal luminal diameter (MLD) before angioplasty/reference diameter, and recoil as balloon diameter minus MLD after angioplasty/reference diameter. Multivariate analysis was used to yield independent risk factors for luminal narrowing at follow-up. Predictors of absolute change in MLD were (1) relative gain at angioplasty (gain in millimeters normalized for reference diameter) and (2) lesion length. To allow risk stratification, logistic regression analysis was applied using the decrease in MLD as a binary outcome variable. A decrease in MLD at follow-up of greater than or equal to 0.72 mm was considered significant. Variables retained in the model were: relative gain greater than 0.3 mm (rate ratio 2.9), relative gain 0.2 to 0.3 (rate ratio 2.1), stenosis length greater than or equal to 6.8 (rate ratio 1.7), and thrombus after angioplasty (rate ratio 2.6). Although stretch was significantly related to luminal narrowing at univariate analysis, it was not retained in the multivariate models. A large gain in lumen diameter at angioplasty, dilation of long lesions, and angiographically determined thrombus after angioplasty were found to be accompanied by more severe luminal narrowing at follow-up.


Asunto(s)
Angioplastia Coronaria con Balón , Enfermedad Coronaria/terapia , Vasos Coronarios/fisiopatología , Adulto , Anciano , Análisis de Varianza , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/fisiopatología , Elasticidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Análisis de Regresión , Factores de Riesgo
20.
J Am Coll Cardiol ; 19(2): 258-66, 1992 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-1732350

RESUMEN

Restenosis after coronary angioplasty is the single complication that most limits this revascularization procedure in clinical practice. The process is largely unpredictable and the lesion-related factors predisposing to restenosis are poorly understood, with little consensus in published reports. In this study using detailed quantitative angiographic measurements to assess 490 lesions, the simple lesion characteristics associated with restenosis were defined and the relation to the restenosis process documented. Restenosis was defined as an absolute deterioration in the minimal lumen diameter by greater than or equal to 0.72 mm, a criterion based on the 95% confidence intervals for repeat angiographic measurements. This was chosen in an attempt to separate spurious changes due to a poor angiographic result and the variability of angiographic measurements from significant changes due to the restenosis process. The principal determinants of restenosis were found to be a large improvement in the minimal lumen diameter at the time of dilation (1.13 mm for the restenosis group compared with 0.86 mm for the no restenosis group [p less than 0.0001]) and an optimal postangioplasty result (minimal lumen diameter 2.28 mm in the restenosis group compared with 2.05 mm [p less than 0.001] in the no restenosis group, corresponding to a 25% and a 30% diameter stenosis, respectively [p less than 0.0001]). These observations reported for the first time suggest that the distinction needs to be made between a "clinical restenosis" of greater than or equal to 50% diameter stenosis and the "restenosis process" as measured by the absolute changes occurring during and after angioplasty.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Angioplastia Coronaria con Balón , Enfermedad Coronaria/terapia , Vasos Coronarios/patología , Constricción Patológica/epidemiología , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/epidemiología , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Recurrencia , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA